Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Bioceres Crop Solutions (BIOX) EBT (2016 - 2026)

Bioceres Crop Solutions' EBT history spans 5 years, with the latest figure at -$14.1 million for Q1 2026.

  • On a quarterly basis, EBT fell 1075.0% to -$14.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$27.1 million, a 83.61% decrease, with the full-year FY2025 number at -$57.6 million, down 620.18% from a year prior.
  • EBT hit -$14.1 million in Q1 2026 for Bioceres Crop Solutions, down from -$1.2 million in the prior quarter.
  • Over the last five years, EBT for BIOX hit a ceiling of -$1.2 million in Q1 2025 and a floor of -$14.1 million in Q1 2026.
  • Historically, EBT has averaged -$8.0 million across 3 years, with a median of -$8.8 million in 2022.
  • Biggest five-year swings in EBT: tumbled 190.11% in 2022 and later crashed 1075.0% in 2026.
  • Tracing BIOX's EBT over 3 years: stood at -$8.8 million in 2022, then surged by 86.36% to -$1.2 million in 2025, then crashed by 1075.0% to -$14.1 million in 2026.
  • Business Quant data shows EBT for BIOX at -$14.1 million in Q1 2026, -$1.2 million in Q1 2025, and -$8.8 million in Q2 2022.